University of South Florida

Washington University

Case Western Reserve University

John H Adams

Francis B Ntumngia

Samantha Jones Barnes

Niraj H Tolia

Nichole Diane Salinas

Christopher L King

Edwin Chen

Miriam Thankam George

Alison Elizabeth Roth

Jesse L Schloegel

Amy M McHenry

Patchanee Chootong

Bill J Baker

Nerida G Wilson

Hirdesh Kumar

Allison Roth

Matthew A Knestrick

Shulin Xu

Darya Urusova

John Jimah

Provided herein are syntheticantigens, antibodies and pharmaceutical formulations and vaccines thereof. Also provided herein are methods of treating and/or preventinginfection and/or disease by administering the syntheticantigens, antibodies and pharmaceutical formulations and vaccines thereof.

Synthetic plasmodium antigens, compositions, and uses thereof

The present disclosure provides immunogenic compositions and methods for vaccination with a CelTOS immunogen. The immunogenic composition comprisesorCelTOS. The immunogenic composition may also comprise CelTOS with structural changes that affect immune recognition.

Compositions comprising CelTOS immunogens and antibodies and method of use thereof

Described herein are compositions and methods to cryopreserve sporozoites. In some aspects, the method can include the step of placing harvested salivary glands containing sporozoites into an insect-based medium.

Sporozoite cryopreservation compositions and methods

Described herein are compounds, formulations, and methods for blocking sporozoite invasion and subsequent liver-stage parasite development of a protozoan parasite, such as

Compounds and methods for inhibiting protozoan parasites

The disclosure provides compositions that are useful for eliciting a strain-transcending immune response in an animal or human directed against the blood-stage of the malarial parasite. The compositions are based on the ligand domain ofDuffy binding protein (PvDBPII). Polar charged polymorphic residues within the dominant strain-specific B-cell epitope were mutated to uncharged residues (e.g. serine, alanine and threonine). This DEKnull variant of PvDBPII produced in bacteria can be purified and refolded in vitro to mimic conformation and erythrocyte binding function of native DBPII. Immunogenicity of DEKnull was confirmed by administration to mice. Compared to the naturally-occurring, strain variant DBPII, DEKnull elicits antibodies that are more broadly reactive with different strain variants of DBPII and enhances production of functional inhibitory antibodies to the shared protective epitopes of native DBPII.

Synthetic antigen based on the ligand domain of the plasmodium vivax duffy binding protein

[object Object]

Growing community of inventors

Tampa, FL, United States of America

John H Adams